Associated tags: TSX, Patient, Pharmaceutical industry, Methotrexate, Hematopoietic stem cell transplantation, Hematology, Customer service, Blood, Treosulfan, Rheumatoid arthritis, Allergy, Health Canada, FDA, Collaboration, World Health Organization, Glioma
The agreement with G. Pohl-Boskamp GmbH & Co KG("Pohl-Boskamp") provides the Company with exclusive Canadian distribution rights for NYDA and includes a commitment related to bringing new and innovative solutions to the Canadian market.
Key Points:
- The agreement with G. Pohl-Boskamp GmbH & Co KG("Pohl-Boskamp") provides the Company with exclusive Canadian distribution rights for NYDA and includes a commitment related to bringing new and innovative solutions to the Canadian market.
- The initial agreement with Pohl-Boskamp was signed in 2011 and the first extension was announced in June 2015.
- Richard Labelle, Vice President Allergy, Pediatric and OTC Portfolios, commented, The renewal and expansion of the agreement is the result of the solid relationship established over the years and based on the success achieved by NYDA since its introduction in the Canadian market in 2012.
- Medexus is excited to extend this partnership that has resulted in a market leader in the category.
Retrieved on:
Thursday, January 21, 2021
TORONTO, CHICAGO and MONTREAL, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)announced today that it has submitted its application to list on The Nasdaq Capital Market (the Nasdaq).
Key Points:
- TORONTO, CHICAGO and MONTREAL, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)announced today that it has submitted its application to list on The Nasdaq Capital Market (the Nasdaq).
- Ken dEntremont, Chief Executive Officer of Medexus, commented, The submission of our application to list on the Nasdaq marks a significant milestone for Medexus.
- Our application is currently under review with Nasdaq staff and we intend to provide further updates as developments unfold.
- The listing of the Companys common shares on the Nasdaq remains subject to the approval of the Nasdaq and the satisfaction of all applicable listing and regulatory requirements.
Retrieved on:
Wednesday, January 6, 2021
TORONTO and CHICAGO and MONTREAL, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)announced today that it has engaged Independent Trading Group (ITG), Inc. (ITG) to provide market-making services to the Company in accordance with TSX Venture Exchange (TSXV) policies.
Key Points:
- TORONTO and CHICAGO and MONTREAL, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)announced today that it has engaged Independent Trading Group (ITG), Inc. (ITG) to provide market-making services to the Company in accordance with TSX Venture Exchange (TSXV) policies.
- Pursuant to the terms of a services agreement (the Services Agreement), ITG will receive compensation of C$5,000 per month (plus applicable taxes), payable on the first business day of each month, for an initial term of three months, with services commencing on January 6, 2021.
- The Services Agreement will automatically renew for additional one-month terms unless terminated by either party in accordance with the terms and conditions of the Services Agreement.
- The Services Agreement may be terminated by either party with 30 days notice.
Retrieved on:
Monday, December 21, 2020
Articles,
Corporate law,
Private law,
Business,
Inheritance,
Labour law,
Property law,
Vesting,
Board of directors,
Corporate governance,
OTC Markets Group TORONTO and CHICAGO and MONTREAL, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)announced today that the board of directors of the Company (the Board) has formally granted (the Annual Grants) restricted share units (RSUs) and stock options (Options) to the Companys non-executive directors pursuant to the Companys previously-approved annual director compensation framework.
Key Points:
- TORONTO and CHICAGO and MONTREAL, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731)announced today that the board of directors of the Company (the Board) has formally granted (the Annual Grants) restricted share units (RSUs) and stock options (Options) to the Companys non-executive directors pursuant to the Companys previously-approved annual director compensation framework.
- The Annual Grants were approved by the Board in November 2020 on the recommendation of the Compensation, Corporate Governance and Nominating Committee of the Board as part of the Companys overall director compensation program.
- Each vested RSU entitles the applicable holder to receive one common share of the Company at a price of $0.01 per common share.
- The RSUs and Options are each exercisable by delivering an exercise notice to the Company in accordance with the Companys 2018 omnibus equity incentive plan and the terms of the applicable award agreement.
Retrieved on:
Friday, December 18, 2020
Steroids,
Drugs,
Glucocorticoids,
Organic compounds,
Pregnanes,
Diketones,
Acetonides,
Organofluorides,
Triamcinolone,
Medroxyprogesterone acetate,
Estradiol enantate TORONTO and CHICAGO and MONTREAL, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company orMedexus) (TSXV: MDP) (OTCQX: MEDXF)(Frankfurt: P731) is pleased to announce it has entered into an exclusive license agreement with Ethypharm (Ethypharm) to register and commercialize Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) in the United States.
Key Points:
- TORONTO and CHICAGO and MONTREAL, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company orMedexus) (TSXV: MDP) (OTCQX: MEDXF)(Frankfurt: P731) is pleased to announce it has entered into an exclusive license agreement with Ethypharm (Ethypharm) to register and commercialize Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) in the United States.
- It is the longest-acting corticosteroid for intra articular injection, often lasting twice as long as competitive products.
- Medexus will also pay a double-digit royalty to Ethypharm on net sales of TH in the United States.
- Ken dEntremont, Chief Executive Officer of Medexus, commented, There has been a long-standing drug shortage of Triamcinolone Hexacetonide in North America due to previous manufacturing issues.
Retrieved on:
Tuesday, December 8, 2020
TORONTO and CHICAGO and MONTREAL, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) ( TSXV: MDP , OTCQX: MEDXF ), today announced that it will be presenting at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15th at 8:00 a.m. PST / 11:00 a.m. EST.
Key Points:
- TORONTO and CHICAGO and MONTREAL, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) ( TSXV: MDP , OTCQX: MEDXF ), today announced that it will be presenting at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15th at 8:00 a.m. PST / 11:00 a.m. EST.
- Ken dEntremont, Chief Executive Officer of Medexus, and Roland Boivin, Chief Financial Officer of Medexus, will be presenting to a live, virtual audience.
- The Main Event will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform.
- View Medexus Pharmaceuticals profile here: https://www.ldmicro.com/profile/MDP.V
Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform.
Retrieved on:
Monday, November 16, 2020
The product was shipped in October 2020 and the revenue has been recognized in the fiscal third quarter ending December 31, 2020.
Key Points:
- The product was shipped in October 2020 and the revenue has been recognized in the fiscal third quarter ending December 31, 2020.
- Achieved operating income of $0.6 million, compared to an operating loss of $1.3 million for the same period last year.
- Operating income for the three-month period ended September 30, 2020, was $0.6 million, compared to an operating loss of $1.3 million for the three-month period ended September 30, 2019.
- Adjusted EBITDA*for the three-month period ended September 30, 2020 was $3.0 million compared to $0.5 million for the three-month period ended September 30, 2019.
Retrieved on:
Monday, November 16, 2020
IXINITY is an FDA approved intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B.
Key Points:
- IXINITY is an FDA approved intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B.
- In January 2020, Aptevo had already commenced dosing patients in a Phase 4 clinical trial to evaluate the safety and efficacy of IXINITY in previously treated patients under 12 years of age with hemophilia B.
- Since the pediatric segment is estimated to represent one-third of the hemophilia B population, a label expansion represents a possible expansion of the potential for IXINITY.
- We remain determined to advance our IXINITY Phase 4 pediatric clinical trial and look forward to providing further updates as we achieve key milestones.
MONTREAL, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, November 17, 2020 to discuss the Companys financial results for the fiscal 2021 second quarter ended September 30, 2020, as well as the Companys corporate progress and other developments.
Key Points:
- MONTREAL, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the Company or Medexus) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, November 17, 2020 to discuss the Companys financial results for the fiscal 2021 second quarter ended September 30, 2020, as well as the Companys corporate progress and other developments.
- The Company expects to file its financial statements along with its MD&A post market on November 16, 2020.
- A webcast replay will be available on the Companys Investor Events section of the website ( https://www.medexus.com/en_US/investors/news-events ) through Wednesday, February 17, 2021.
- Medexus Pharmaceuticals is focused on the therapeutic areas of auto-immune disease, hematology and allergy.
The services contemplated under the Consulting Agreement include introducing the Company to various institutional investors, fund managers, family offices and other potential investors throughout Europe.
Key Points:
- The services contemplated under the Consulting Agreement include introducing the Company to various institutional investors, fund managers, family offices and other potential investors throughout Europe.
- Westmount is owned by Robert E. Seguin and is arms length to the Company.
- As of the date hereof, Westmount does not have any interest, directly or indirectly, in the Company or its securities, or any right or intent to acquire such an interest.
- Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform.
